Prognostic significance of metabolomic biomarkers in patients with diabetes mellitus and coronary artery disease

Efstratios Karagiannidis, Dimitrios V Moysidis, Andreas S Papazoglou, Eleftherios Panteris, Olga Deda, Nikolaos Stalikas, Georgios Sofidis, Anastasios Kartas, Alexandra Bekiaridou, George Giannakoulas, Helen Gika, George Theodoridis, Georgios Sianos, Efstratios Karagiannidis, Dimitrios V Moysidis, Andreas S Papazoglou, Eleftherios Panteris, Olga Deda, Nikolaos Stalikas, Georgios Sofidis, Anastasios Kartas, Alexandra Bekiaridou, George Giannakoulas, Helen Gika, George Theodoridis, Georgios Sianos

Abstract

Background: Diabetes mellitus (DM) and coronary artery disease (CAD) constitute inter-related clinical entities. Biomarker profiling emerges as a promising tool for the early diagnosis and risk stratification of either DM or CAD. However, studies assessing the predictive capacity of novel metabolomics biomarkers in coexistent CAD and DM are scarce.

Methods: This post-hoc analysis of the CorLipid trial (NCT04580173) included 316 patients with CAD and comorbid DM who underwent emergency or elective coronary angiography due to acute or chronic coronary syndrome. Cox regression analyses were performed to identify metabolomic predictors of the primary outcome, which was defined as the composite of major adverse cardiovascular or cerebrovascular events (MACCE: cardiovascular death, myocardial infarction, stroke, major bleeding), repeat unplanned revascularizations and cardiovascular hospitalizations. Linear regression analyses were also performed to detect significant predictors of CAD complexity, as assessed by the SYNTAX score.

Results: After a median 2-year follow up period (IQR = 0.7 years), the primary outcome occurred in 69 (21.8%) of patients. Acylcarnitine ratio C4/C18:2, apolipoprotein (apo) B, history of heart failure (HF), age > 65 years and presence of acute coronary syndrome were independent predictors of the primary outcome in diabetic patients with CAD (aHR = 1.89 [1.09, 3.29]; 1.02 [1.01, 1.04]; 1.28 [1.01, 1.41]; 1.04 [1.01, 1.05]; and 1.12 [1.05-1.21], respectively). Higher levels of ceramide ratio C24:1/C24:0, acylcarnitine ratio C4/C18:2, age > 65 and peripheral artery disease were independent predictors of higher CAD complexity (adjusted β = 7.36 [5.74, 20.47]; 3.02 [0.09 to 6.06]; 3.02 [0.09, 6.06], respectively), while higher levels of apoA1 were independent predictors of lower complexity (adjusted β= - 0.65 [- 1.31, - 0.02]).

Conclusions: In patients with comorbid DM and CAD, novel metabolomic biomarkers and metabolomics-based prediction models could be recruited to predict clinical outcomes and assess the complexity of CAD, thereby enabling the integration of personalized medicine into routine clinical practice. These associations should be interpreted taking into account the observational nature of this study, and thus, larger trials are needed to confirm its results and validate them in different and larger diabetic populations.

Keywords: Coronary artery disease; Diabetes mellitus; Metabolomic profiling; Metabolomics biomarkers; SYNTAX score.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Significant parameters derived from the multivariable Cox regression models set for the prediction of the primary outcome. *ACS, acute coronary syndrome; CCS, chronic coronary syndrome; aHR, adjusted hazard ratio; CAD, coronary artery disease
Fig. 2
Fig. 2
Receiver operating characteristic (ROC) analysis on the predictive capacity of the created multivariable Cox regression model for the occurrence of adverse clinical outcomes in patients with CAD and DM. ROC analysis on the predictive capacity of the created multivariable Cox regression model for the identification of the hazard for the primary composite outcome of major adverse cardiovascular or cerebrovascular events (MACCE; cardiovascular death, stroke, myocardial infarction, major bleeding), repeat unplanned revascularization and cardiovascular hospitalizations (area under the curve [AUC]: 0.76, 95% CI 0.60–0.87; Chi-square = 23.979, P = 0.017)
Fig. 3
Fig. 3
Significant parameters derived from the multivariable linear regression models set for the prediction of coronary artery disease complexity. *ACS, acute coronary syndrome; CCS, chronic coronary syndrome; β; adjusted beta coefficient; CAD, coronary artery disease
Fig. 4
Fig. 4
Receiver operating characteristic (ROC) analysis on the predictive capacity of the created multivariable linear regression model for the prediction of coronary artery disease complexity in patients with CAD and DM. ROC analysis on the predictive capacity of the developed bootstrapped multivariable linear regression model for the prediction of coronary artery disease complexity (AUC: 0.71, 95% CI 0.60–0.83; R-square = 0.220, Durbin-Watson = 2.131, P = 0.002)

References

    1. Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17:83. doi: 10.1186/s12933-018-0728-6.
    1. Aronson D, Edelman ER. Coronary artery disease and diabetes mellitus. Cardiol Clin. 2014;32:439–455. doi: 10.1016/j.ccl.2014.04.001.
    1. Naito R, Miyauchi K. Coronary artery disease and type 2 diabetes mellitus. Int Heart J. 2017;58:475–480. doi: 10.1536/ihj.17-191.
    1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–2581. doi: 10.1001/jama.287.19.2570.
    1. Esper RB, Farkouh ME, Ribeiro EE, et al. SYNTAX score in patients with diabetes undergoing coronary revascularization in the FREEDOM trial. J Am Coll Cardiol. 2018;72:2826–2837. doi: 10.1016/j.jacc.2018.09.046.
    1. Liu Y, Yang Y, Zhu J, et al. Prognostic significance of hemoglobin A1c level in patients hospitalized with coronary artery disease. A systematic review and meta-analysis. Cardiovasc Diabetol. 2011;10:98. doi: 10.1186/1475-2840-10-98.
    1. Isfort M, Stevens SCW, Schaffer S, et al. Metabolic dysfunction in diabetic cardiomyopathy. Heart Fail Rev. 2014;19:35–48. doi: 10.1007/s10741-013-9377-8.
    1. Ghanassia E, Brun JF, Fedou C, et al. Substrate oxidation during exercise: type 2 diabetes is associated with a decrease in lipid oxidation and an earlier shift towards carbohydrate utilization. Diabetes Metab. 2006;32:604–610. doi: 10.1016/S1262-3636(07)70315-4.
    1. McGarrah RW, Crown SB, Zhang G-F, et al. Cardiovascular metabolomics. Circ Res. 2018;122:1238–1258. doi: 10.1161/CIRCRESAHA.117.311002.
    1. Deidda M, Piras C, Bassareo PP, et al. Metabolomics, a promising approach to translational research in cardiology. IJC Metab Endocr. 2015;9:31–38. doi: 10.1016/j.ijcme.2015.10.001.
    1. Ussher JR, Elmariah S, Gerszten RE, et al. The emerging role of metabolomics in the diagnosis and prognosis of cardiovascular disease. J Am Coll Cardiol. 2016;68:2850–2870. doi: 10.1016/j.jacc.2016.09.972.
    1. Howard BV, Robbins DC, Sievers ML, et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: the strong heart study. Arterioscler Thromb Vasc Biol. 2000;20:830–835. doi: 10.1161/01.ATV.20.3.830.
    1. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115:450–458. doi: 10.1161/CIRCULATIONAHA.106.637793.
    1. Cheng S, Shah SH, Corwin EJ, et al. Potential impact and study considerations of metabolomics in cardiovascular health and disease: a scientific statement from the American Heart Association. Circ Cardiovasc Genet. 2017 doi: 10.1161/HCG.0000000000000032.
    1. Yin X, de Carvalho LP, Chan MY, et al. Integrated metabolomics and metallomics analyses in acute coronary syndrome patients. Metallomics. 2017;9:734–743. doi: 10.1039/C7MT00071E.
    1. Tu C, Xie L, Wang Z, et al. Association between ceramides and coronary artery stenosis in patients with coronary artery disease. Lipids Health Dis. 2020;19:151. doi: 10.1186/s12944-020-01329-0.
    1. Guo F, Zhou J, Li Z, et al. The association between trimethylamine N-oxide and its predecessors choline, L-carnitine, and betaine with coronary artery disease and artery stenosis. Cardiol Res Pract. 2020;2:5854919.
    1. Tabák AG, Carstensen M, Witte DR, et al. Adiponectin trajectories before type 2 diabetes diagnosis: Whitehall II study. Diabetes Care. 2012;35:2540–2547. doi: 10.2337/dc11-2263.
    1. Guasch-Ferré M, Hruby A, Toledo E, et al. Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis. Diabetes Care. 2016;39:833–846. doi: 10.2337/dc15-2251.
    1. Danese E, Montagnana M, Nouvenne A, et al. Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes. J Diabetes Sci Technol. 2015;9:169–176. doi: 10.1177/1932296814567227.
    1. Dorcely B, Katz K, Jagannathan R, et al. Novel biomarkers for prediabetes, diabetes, and associated complications. Diabetes Metab Syndr Obes. 2017;10:345–361. doi: 10.2147/DMSO.S100074.
    1. Papazoglou AS, Kartas A, Samaras A, et al. Prognostic significance of diabetes mellitus in patients with atrial fibrillation. Cardiovasc Diabetol. 2021;20:40. doi: 10.1186/s12933-021-01232-7.
    1. Karagiannidis E, Sofidis G, Papazoglou AS, et al. Correlation of the severity of coronary artery disease with patients’ metabolic profile- rationale, design and baseline patient characteristics of the CorLipid trial. BMC Cardiovasc Disord. 2021;21:79. doi: 10.1186/s12872-021-01865-2.
    1. Deda O, Panteris E, Meikopoulos T, et al. Correlation of serum acylcarnitines with clinical presentation and severity of coronary artery disease. Biomolecules. 2022 doi: 10.3390/biom12030354.
    1. Committee IE. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327–1334. doi: 10.2337/dc09-9033.
    1. Begou OA, Deda O, Karagiannidis E, et al. Development and validation of a RPLC-MS/MS method for the quantification of ceramides in human serum. J Chromatogr B. 2021;1175:122734. doi: 10.1016/j.jchromb.2021.122734.
    1. Meikopoulos T, Deda O, Karagiannidis E, et al. A HILIC-MS/MS method development and validation for the quantitation of 13 acylcarnitines in human serum. Anal Bioanal Chem. 2022 doi: 10.1007/s00216-022-03940-9.
    1. Sianos G, Morel M-A, Kappetein AP, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention J Eur Collab Work Gr Interv Cardiol Eur Soc Cardiol. 2005;1:219–227.
    1. Garber DW, Handattu SP, Datta G, et al. Atherosclerosis and vascular disease: effects of peptide mimetics of apolipoproteins. Curr Pharm Biotechnol. 2006;7:235–240. doi: 10.2174/138920106777950834.
    1. Barrett TJ, Distel E, Murphy AJ, et al. Apolipoprotein AI promotes atherosclerosis regression in diabetic mice by suppressing myelopoiesis and plaque inflammation. Circulation. 2019;140:1170–1184. doi: 10.1161/CIRCULATIONAHA.119.039476.
    1. Bhanpuri NH, Hallberg SJ, Williams PT, et al. Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study. Cardiovasc Diabetol. 2018;17:56. doi: 10.1186/s12933-018-0698-8.
    1. Avogaro P, Bon GB, Cazzolato G, et al. Are apolipoproteins better discriminators than lipids for atherosclerosis? Lancet (London, England) 1979;1:901–903. doi: 10.1016/S0140-6736(79)91375-8.
    1. Sniderman AD, Robinson JG. ApoB in clinical care: pro and con. Atherosclerosis. 2019;282:169–175. doi: 10.1016/j.atherosclerosis.2018.11.001.
    1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Eur Heart J. 2020;41:111–188. doi: 10.1093/eurheartj/ehz455.
    1. Florvall G, Basu S, Larsson A. Apolipoprotein A1 is a stronger prognostic marker than are HDL and LDL cholesterol for cardiovascular disease and mortality in elderly men. J Gerontol A Biol Sci Med Sci. 2006;61:1262–1266. doi: 10.1093/gerona/61.12.1262.
    1. Van Linthout S, Spillmann F, Riad A, et al. Human apolipoprotein A-I gene transfer reduces the development of experimental diabetic cardiomyopathy. Circulation. 2008;117:1563–1573. doi: 10.1161/CIRCULATIONAHA.107.710830.
    1. Deng F, Li D, Lei L, et al. Association between apolipoprotein B/A1 ratio and coronary plaque vulnerability in patients with atherosclerotic cardiovascular disease: an intravascular optical coherence tomography study. Cardiovasc Diabetol. 2021;20:188. doi: 10.1186/s12933-021-01381-9.
    1. Neumann JT, Twerenbold R, Ojeda F, et al. Application of high-sensitivity troponin in suspected myocardial infarction. N Engl J Med. 2019;380:2529–2540. doi: 10.1056/NEJMoa1803377.
    1. Tang O, Daya N, Matsushita K, et al. Performance of high-sensitivity cardiac troponin assays to reflect comorbidity burden and improve mortality risk stratification in older adults with diabetes. Diabetes Care. 2020;43:1200–1208. doi: 10.2337/dc19-2043.
    1. Lan NSR, Bell DA, McCaul KA, et al. High-sensitivity cardiac troponin I improves cardiovascular risk prediction in older men: HIMS (The Health in Men Study) J Am Heart Assoc. 2019;8:e011818. doi: 10.1161/JAHA.118.011818.
    1. Strand E, Pedersen ER, Svingen GFT, et al. Serum acylcarnitines and risk of cardiovascular death and acute myocardial infarction in patients with stable angina pectoris. J Am Heart Assoc. 2017;6:e003620. doi: 10.1161/JAHA.116.003620.
    1. Ribel-Madsen A, Ribel-Madsen R, Brøns C, et al. Plasma acylcarnitine profiling indicates increased fatty acid oxidation relative to tricarboxylic acid cycle capacity in young, healthy low birth weight men. Physiol Rep. 2016 doi: 10.14814/phy2.12977.
    1. Zhao S, Feng X-F, Huang T, et al. The association between acylcarnitine metabolites and cardiovascular disease in chinese patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne) 2020;11:212. doi: 10.3389/fendo.2020.00212.
    1. Shah SH, Sun J-L, Stevens RD, et al. Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. Am Heart J. 2012;163:844–850.e1. doi: 10.1016/j.ahj.2012.02.005.
    1. Shah SH, Bain JR, Muehlbauer MJ, et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet. 2010;3:207–214. doi: 10.1161/CIRCGENETICS.109.852814.
    1. Vasile VC, Meeusen JW, Medina Inojosa JR, et al. Ceramide scores predict cardiovascular risk in the community. Arterioscler Thromb Vasc Biol. 2021;41:1558–1569. doi: 10.1161/ATVBAHA.120.315530.
    1. Cogolludo A, Villamor E, Perez-Vizcaino F, et al. Ceramide and regulation of vascular tone. Int J Mol Sci. 2019;20:411. doi: 10.3390/ijms20020411.
    1. Karagiannidis E, Papazoglou AS, Stalikas N. Serum ceramides as prognostic biomarkers of large thrombus burden in patients with STEMI: a micro-Computed Tomography study. J Pers Med. 2021 doi: 10.20944/preprints202101.0093.v1.
    1. Choi RH, Tatum SM, Symons JD, et al. Ceramides and other sphingolipids as drivers of cardiovascular disease. Nat Rev Cardiol. 2021;18:701–711. doi: 10.1038/s41569-021-00536-1.
    1. Hilvo M, Vasile VC, Donato LJ, et al. Ceramides and ceramide scores: clinical applications for cardiometabolic risk stratification. Front Endocrinol (Lausanne) 2020;11:570628. doi: 10.3389/fendo.2020.570628.
    1. Vizirianakis IS, Chatzopoulou F, Papazoglou AS, et al. The GEnetic Syntax Score: a genetic risk assessment implementation tool grading the complexity of coronary artery disease—rationale and design of the GESS study. BMC Cardiovasc Disord. 2021;21:284. doi: 10.1186/s12872-021-02092-5.

Source: PubMed

Подписаться